GSK has agreed to acquire Canada’s Bellus Health for around $2 billion, bolting on a late-stage drug candidate for chronic refractory cough. The $14.75-per-share deal will add P2X3 antagonist ...

THERE is a passage in the “Germania” of Tacitus (chapter xlv.) which I do not think can have ever been examined by the historians of natural science, or it would have created a considerable stir ...

The FDA has issued a complete response letter (CRL) to Merck & Co's gefapixant candidate for refractory chronic cough, delaying the programme and giving Bayer an opportunity to close the gap with its ...